Cleveland-based medical device company SPR Therapeutics raised $37 million in series D funding for its peripheral nerve stimulation system, the company said Oct. 18 in a news release.
The system involves one or two thin leads implanted under the skin, which deliver pulses of electricity to the nerves to block or reduce pain signals.
The FDA recently approved the 60-day device for a broader range of applications, including treatment in the head, neck and front of the torso, SPR said in an Oct. 19 news release.